Your session is about to expire
← Back to Search
Ofatumumab for Multiple Sclerosis
Study Summary
This trialtests if a medication can help people mount an adequate immune response to the flu vaccine.
- Multiple Sclerosis (MS)
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 319 Patients • NCT02004522Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What have been the reported adverse effects associated with Ofatumumab treatment?
"Our team has rated the safety of Ofatumumab a 3, owing to its Phase 4 status. This implies that this drug is approved and available for public use."
Is there any availability for new participants in this research project?
"As per clinicaltrials.gov, this investigation has commenced recruitment of participants; the trial was first advertised on January 14th 2021 and most recently revised on December 5th 2022."
How many participants are included in the study cohort?
"Affirmative. Clinicaltrials.gov indicates that this research is currently seeking applicants, which were first posted on January 14th 2021 and modified as recently as December 5th 2022. The study requires 66 participants to be recruited from 4 different sites."
Has anything like this been attempted before?
"As of now, 24 active clinical trials utilizing Ofatumumab are being conducted in 292 cities and 45 countries. The initial investigation of this therapeutic agent began back in 2010 when GlaxoSmithKline sponsored a Phase 2 trial that included 32 participants; since then, 77 additional studies have been concluded."
In what ways is Ofatumumab utilized to improve patient health?
"Ofatumumab is regularly prescribed to patients suffering from multiple sclerosis, as well as those with refractory fludarabine and alemtuzumab, who are unable to utilize fludarabine-based therapies, or have active secondary progressive multiple sclerosis (spms)."
Is it possible to register for participation in this clinical trial?
"66 individuals aged between 18 and 55 who have been diagnosed with multiple sclerosis are required for this medical trial. Moreover, they must intend to receive the 2020-2021 inactivated influenza vaccine, remain willing to observe the study's timeline and be compliant throughout."
How many medical institutions are currently hosting this research trial?
"In order to reduce the burden of travel, prospective participants should select one of 4 trial sites that are closest to them. These locations include Sunrise, Saint Louis and Vienna amongst a few other destinations."
What prior investigations involving Ofatumumab have taken place?
"Of the 24 studies currently examining Ofatumumab, 6 are in Phase 3. Most of these trials are taking place in Houston, Texas; however, global participation is available from 753 sites across multiple countries."
Is the trial open to individuals aged fifty and above?
"This clinical trial has specific age parameters for participation, with a floor of 18 years old and a ceiling of 55."
Share this study with friends
Copy Link
Messenger